杭州市上城区新业路8号华联时代大厦 B 幢22层 电话:0571-88362156 传真:0571-88362156 邮编:310016 北京国枫(杭州)律师事务所 关于振德医疗用品股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]G0015 号 致: 振德医疗用品股份有限公司(贵公司) 北京国枫(杭州)律师事务所(以下简称"本所")接受贵公司的委托,指派律师 出席并见证贵公司 2025年第一次临时股东大会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《振德医疗用品股份 有限公司章程》(以下简称"《公司章程》"）的规定,就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本法律意见 ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-029 振德医疗用品股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 8 月 11 日 (二)股东大会召开的地点：浙江省绍兴市越城区皋埠街道香积路 55 号振德医 疗 用品股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 160 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 173,102,789 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 64.9660 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 本次会议由公司董事会召集，以现场投票和网络投票相结合的方式召开，由 董事长鲁建国先生主持会议。本次会 ...

Group 1 - The company, Zhendemedical, announced the convening of its fourth board meeting on August 11, 2025, to discuss the election of the chairman and vice-chairman [2] - For the year 2024, Zhendemedical's revenue composition indicates that medical dressings accounted for 99.61% of total revenue, while other businesses contributed 0.39% [2]

证券代码：603301 证券简称：振德医疗 公告编号：2025-030 振德医疗用品股份有限公司 第四届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第四届董事会 第一次会议于 2025 年 8 月 11 日在公司会议室以现场方式召开，第四 届董事会全体董事一致同意豁免本次会议提前通知时限，与会董事均 已知悉与所议事项相关的必要信息。本次会议由公司董事鲁建国先生 主持，会议应出席董事 9 名，实际出席董事 9 名，公司高级管理人员 列席了本次会议，符合《公司法》和《公司章程》的有关规定，决议 合法有效。 会议审议议案后形成以下决议： 1、审议通过《关于选举公司董事长、副董事长的议案》。 董事会选举鲁建国先生为公司第四届董事会董事长，沈振芳女士 为公司第四届董事会副董事长，任期为三年，自本次董事会审议通过 之日起至第四届董事会届满之日止。鲁建国先生和沈振芳女士的简历 详 见 公 司 于 2025 年 7 月 24 日 在 上 海 证 券 交 易 所 网 站 ...

Group 1 - The core point of the news is that Zhend Medical has seen a net buying of 4.6286 million yuan in financing on August 8, 2023, with a financing buy amount of 0.10 billion yuan, ranking 1239th in the market [1] - Over the last three trading days from August 6 to August 8, Zhend Medical received financing buy amounts of 0.06 billion yuan, 0.05 billion yuan, and 0.10 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold short, but there was a net buying of 0.007 million shares [2]

Core Viewpoint - The stock of Zhendemedical (603301) has shown a decline in price and mixed capital flow, indicating potential volatility in the market [1][2]. Financial Performance - As of August 6, 2025, Zhendemedical's stock closed at 22.08 yuan, down 1.3% with a trading volume of 27,700 hands and a transaction amount of 61.39 million yuan [1]. - The company reported a main revenue of 992 million yuan for Q1 2025, a year-on-year increase of 2.87%, while the net profit attributable to shareholders was 51.24 million yuan, a decrease of 30.19% year-on-year [4]. - The company's gross profit margin stands at 34.28%, which is significantly lower than the industry average of 51.31% [4]. Capital Flow Analysis - On August 6, 2025, the net outflow of main funds was 5.89 million yuan, accounting for 9.6% of the total transaction amount, while retail investors saw a net inflow of 7.72 million yuan, representing 12.57% of the total [1]. - Over the past five days, the financing balance has increased, with a net financing purchase of 2.25 million yuan on August 6, 2025, contributing to a cumulative net purchase of 14.04 million yuan over three days [2]. Industry Comparison - Zhendemedical's total market value is 5.883 billion yuan, which is below the industry average of 11.525 billion yuan, ranking 59th out of 123 companies in the medical device sector [4]. - The company's price-to-earnings ratio (P/E) is 28.7, significantly lower than the industry average of 61.65, indicating a potentially undervalued stock [4]. Institutional Ratings - In the last 90 days, two institutions have rated Zhendemedical with a "buy" recommendation, and the average target price set by institutions is 27.13 yuan [5].

Group 1 - The core point of the news is that Zhend Medical has seen a notable increase in financing buy-in amounts over the recent trading days, indicating potential investor interest [1] - On August 5, Zhend Medical recorded a financing buy-in amount of 0.13 billion, ranking 1056th in the market, with a financing repayment amount of 0.04 billion, resulting in a net buy-in of 9.0342 million [1] - Over the last three trading days (August 1-5), Zhend Medical received financing buy-ins of 0.06 billion, 0.06 billion, and 0.13 billion respectively [1] Group 2 - In terms of securities lending, on the same day, Zhend Medical had a securities lending sell-out of 0.05 thousand shares, with a net sell-out of 0.04 thousand shares [2]

振德医疗用品股份有限公司的主营业务是医疗和健康产品的研发、生产与销售。公司的主要产品是基础 护理、手术感控、压力治疗与固定、造口及现代伤口护理、感控防护。公司曾先后获得包括省级重点企 业研究院、省级工程技术研究中心、省级高新技术企业研究中心、省级企业技术中心、省创新型试点企 业、省级专利示范企业在内的多项技术奖项，并通过国家高新技术企业评审。 8月4日，振德医疗今日收盘22.42元，上涨1.04%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.46倍，创145天以来新低，总市值59.74亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，振德医疗排 名第36位。 截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗16.4615.511.0559.74 ...

Core Viewpoint - Zhendemedical (603301) has seen a stock price increase of 0.91% to 22.19 yuan as of August 1, 2025, with a total market capitalization of 5.913 billion yuan [1] Company Announcements - The company announced the election of Zhang Xiantao as the employee representative director for the fourth board of directors, following the expiration of the third board's term [1][4] - The first extraordinary general meeting of shareholders in 2025 will be held on August 11, 2025, to review multiple proposals, including the salary scheme for the fourth board of directors and the cancellation of the supervisory board [2][3] - The company plans to cancel the supervisory board, transferring its powers to the audit committee of the board of directors [2][4] - The registered capital will be reduced from 266,451,202 yuan to 265,835,535 yuan [2][4] - The business scope will be expanded to include the sale of sanitary insecticides [2][4] - The company will repurchase 615,667 shares from the first employee stock ownership plan at a price of 25.16 yuan per share, changing the purpose of the repurchased shares from "implementation of employee stock ownership plan" to "cancellation and reduction of registered capital" [3][4]

Meeting Details - The first extraordinary general meeting of shareholders for 2025 will be held in the company's conference room [1] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for each [1][5] - Shareholders registered in the company's records have the right to attend and vote at the meeting [1] Agenda Items - The meeting will review several proposals, including the fourth board of directors' remuneration plan and the cancellation of the supervisory board [3][7] - Other proposals include changes to the company's registered capital, expansion of business scope, and amendments to the company's articles of association [3][7][9] - The company plans to cancel the supervisory board, transferring its powers to the audit committee of the board of directors [7] Financial Proposals - The proposed remuneration for the fourth board of directors is set at RMB 150,000 per year, inclusive of taxes [6] - The company intends to cancel 615,667 shares from the first employee stock ownership plan, reducing the total share capital from 266,451,202 shares to 265,835,535 shares [7][9] Business Scope Changes - The company aims to expand its business scope to include additional medical and healthcare products, such as first-class medical devices and non-medical masks [8][10] - The revised business scope will also cover various manufacturing and sales activities related to personal protective equipment and daily chemical products [9][10] Governance and Compliance - The company will amend its articles of association to reflect changes in governance structure and business operations [10][11] - The amendments will ensure compliance with relevant laws and regulations, enhancing the protection of shareholders' rights [11][12]